Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
source: pixabay.com
In a press release from March 3, 2021, biotechnology company BioMarin Pharmaceutical Inc. ("BioMarin") shared that it had completed full enrollment for a Phase 2 clinical trial evaluating vosoritide for…
Continue Reading
Vosoritide Trial for Achondroplasia Fully Enrolled
source: pixabay.com
At the beginning of March 2021, gene therapy company AVROBIO, Inc. shared that its investigational gene therapy, AVR-RD-04, was given Orphan Drug designation by the European Commission (EC). This treatment…
Continue Reading
AVR-RD-04 for Cystinosis Granted Orphan Drug Designation from EC
Source: Pixabay
In a joint statement, biopharmaceutical companies AstraZeneca and Merck & Co., Inc. ("Merck") shared that LYNPARZA (olaparib) achieved a superiority boundary in the Phase 3 OlympiA clinical trial. During…
Continue Reading
LYNPARZA Trial for BRCA-Mutated HER2-Negative Breast Cancer Achieved iDFS Superiority Boundary
According to a recent press release, neuropharmaceutical company NeurAegis Inc. shared the publication of some study data which explored calpain-2 as a potential therapeutic target for status epilepticus (SE). The…
Continue Reading
New Published Data on Calpain-2 for Status Epilepticus
During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…
Continue Reading
Updates Available on Givinostat Clinical Development for DMD
An estimated 1 in 10 Americans, or 1 in 20 people globally, have or will have a rare disease at some point. Rare Disease Day takes place on February 28. Ultimately,…
Continue Reading
“Pinpoint PF:” Learning about Pulmonary Fibrosis
According to a February 25 press release, Amondys 45 (casimersen), a therapeutic option for patients with Duchenne muscular dystrophy (DMD), recently became FDA-approved. The therapy is specifically designed for patients…
Continue Reading
Amondys 45 Approved for DMD
On February 18, 2021, specialty pharmaceutical company Kyowa Kirin Co., Ltd. ("Kyowa Kirin") shared that a Phase 2 clinical trial evaluating KHK4083 had reached its primary endpoint. KHK4083 is an…
Continue Reading
KHK4083 Shows Promise for Severe Atopic Dermatitis
In some cases, elderly patients (those over 70 years old) with esophageal cancer have been told that surgery is not the best option. This stems from a belief that…
Continue Reading
Surgery Offers Benefits to Elderly Patients with Esophageal Cancer
Photo by Robina Weermeijer on Unsplash
February 28th is known as Rare Disease Day, designed to raise awareness of rare diseases, patients, caregivers, and their experiences. As this day approaches, the American Kidney Fund (AKF) shared…
Continue Reading
AKF Highlights PH in New Awareness Campaign
In 2007, biotechnology company Seagen Inc. and pharmaceutical company Astellas Pharma Inc. ("Astellas") collaborated to develop enfortumab vedotin. Now, in 2021, the pair submitted two supplemental Biologics License Applications (sBLAs)…
Continue Reading
Two sBLAs Submitted for PADCEV for Urothelial Cancer
source: pixabay.com
During clinical development, treatments are sometimes first evaluated in healthy volunteers. This is the route that Insmed Incorporated ("Insmed") took with treprostinil palmitil inhalation powder (TPIP). Now, following positive topline…
Continue Reading
Positive Topline Results Available on TPIP for PAH
After discovering that some pancreatic cancer expresses high amounts of intratumoral interferon signaling (IFN), researchers wondered whether they could create a new plan of treatment. According to Medical XPress,…
Continue Reading
Combination Therapy Could Halt Pancreatic Cancer Tumor Growth
Source: pixabay.com
Recently, botanical pharmaceutical company Devonian Health Group Inc. ("Devonian") has been evaluating its product thykamine for patients with mild-to-moderate atopic dermatitis in a Phase 2 clinical trial. In a…
Continue Reading
Thykamine for Atopic Dermatitis Met Primary Trial Endpoint
source: pixabay.com
Biotechnology company Stealth Biotherapeutics ("Stealth") has made the company's mission to develop and commercialize treatments for patients with diseases characterized by mitochondrial dysfunction. One leading treatment in the company's…
Continue Reading
Full Enrollment in ReCLAIM-2 Trial for Dry Macular Degeneration
source: pixabay.com
As many patients in the rare disease community know, achieving a diagnosis can be a lengthy and difficult journey. Following this journey, it can still take a while to receive…
Continue Reading
New Clinical Guidelines Available on VWD Diagnosis and Management
source: pixabay.com
Recently, clinical stage biopharmaceutical company Immunic, Inc. ("Immunic") has been working to develop potential treatment options for patients with primary sclerosing cholangitis (PSC), a rare condition for which no…
Continue Reading
Positive Top-Line Data Available from IMU-838 Trial for PSC
Source: pixabay.com
New research suggests that ultrasounds could be a new diagnostic tool for patients with a rare lysosomal storage disorder. According to Fabry Disease News, kidney dysfunction is characteristic in Fabry…
Continue Reading
Could Ultrasounds Quicken Fabry Disease Diagnosis?
source: pixabay.com
According to a recent press release, scientists studying the Uniformed Services University of the Health Sciences' (USU) The American Genome Center (TAGC) identified five genes which could play a role…
Continue Reading
Five Genes Identified That May Cause Lewy Body Dementia
source: pixabay.com
For nearly one year now, COVID-19 has dominated our headlines. In 2020, news emerged of SARS-CoV-2, a virus causing a global pandemic. Now, in February 2021, there are 110 million…
Continue Reading
Discussing the New COVID-19 Variants
Just over a week ago, drug discovery and development company Rescindo Therapeutics Inc. ("Rescindo") shared that its drug candidate RSC-57 received both Orphan Drug and Rare Pediatric Disease designations. The…
Continue Reading
RSC-57 for Kabuki Syndrome Receives Orphan Drug and Rare Pediatric Disease Designations
source: pixabay.com
In the past, researchers have questioned the exact cause of spina bifida, a neural tube defect in which the spine does not fully close around the developing spinal cord nerves.…
Continue Reading
Mosaic Mutations May Cause Spina Bifida
According to Targeted Oncology, the first patient was dosed in a Phase 1 clinical trial evaluating NBTXR3, an investigational tumor-agnostic radio enhancer, for patients with esophageal cancer. The trial will…
Continue Reading
First Patient Dosed in NBTXR3 Trial for Esophageal Cancer
source: pixabay.com
While gene therapy is a promising field, there are some associated risks: unwanted immune reactions, infections, or whether the therapy could lead to the development of other conditions, like cancer.…
Continue Reading
SCD Gene Therapy Trials Stop After Patients Develop MDS, AML
source: pixabay.com
Typically, the pathway to diagnosis for endometrial cancer can be long, uncomfortable, and invasive: transvaginal ultrasounds, biopsies. However, this may be about to change. In a recent press release, Arquer…
Continue Reading
ADXGYNAE Identifies Endometrial Cancer Biomarkers in 3 Hours